(Q36565628)

English

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai

scientific article published on 8 January 2013

In more languages
default for all languages
No label defined

No description defined

Statements

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai (English)
Louis P Garrison
Abbie Ba-Mancini
Caroline Korves
Ravinder Dhawan
Helgi van de Velde
Deyanira Corzo

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit